1 November 2010
Responding to the news that NICE will no longer have the power to ban drugs on the National Health Service, Mike Hobday, Head of Policy at Macmillan Cancer Support, said:
'NICE has performed a really important role for the NHS. Having a body that can say ‘no’ to pharmaceutical companies has been crucial in driving the price of drugs down, so that the NHS can afford to support patients more often. But NICE has too often misread the public mood in rejecting clinically effective drugs for rare cancers. It has placed insufficient weight on the importance of allowing the NHS to give patients with rare cancers the drugs that their doctors believe will extend or improve the quality of their lives.
'We are talking to the Government to ensure that, when NICE is reformed, the NHS will provide all cancer patients with access to clinically effective drugs recommended by their doctors.'
For further information, please contact:
Julie Wills, Assistant Media & PR Officer, Macmillan Cancer Support
020 7840 4933
Notes to Editors:
About Macmillan Cancer Support
Macmillan Cancer Support improves the lives of people affected by cancer, providing practical, medical, emotional and financial support. Working alongside people affected by cancer, Macmillan works to improve cancer care. One in three of us will get cancer. Two million of us are living with it. If you are affected by cancer Macmillan can help.
Call the Macmillan Support Line on 0808 808 00 00, Monday to Friday, 9am to 8pm. Calls are free, including from mobiles or visit www.macmillan.org.uk